Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Co    BMY

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

Bristol-Myers Squibb Co : annual earnings release

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/23/2017 | 03:15pm CET
The company will report its earnings for FY 2016 on 01/26/2017. Generally, the company reports earnings better than estimates. In recent months, the 8 analysts from Thomson Reuters consensus have revised their EPS estimates upward.

Annual earnings per share is expected at 2.75 USD for 2016 (+ 183.8% from 2015). A summary of annual publications and estimates is available below.

Annual results2013201420152016 (e)2017 (e)
Sales
Million $
Released
Forecast
Spread
16 385
16 268
0,72%
15 879
15 684
1,2%
16 560
16 405
0,95%

19 312

19 895
Operating income (EBITDA)
Million $
Released
Forecast
Spread
3 668
4 148
-12%
3 935
3 960
-0,62%
4 243
4 231
0,29%

5 714

6 205
Operating profit (EBIT)
Million $
Released
Forecast
Spread
3 454
3 274
5,5%
3 468
3 376
2,7%
3 867
3 670
5,4%

5 358

5 675
Pre-Tax Profit (EBT)
Million $
Released
Forecast
Spread
2 891









Net income
Million $
Released
Forecast
Spread
2 563
2 490
3,0%
2 004
2 355
-15%
1 624
2 220
-27%

4 617

4 676
EPS
 $
Released
Forecast
Spread
1,54
1,50
2,7%
1,20
1,41
-15%
0,97
1,12
-13%

2,75

2,82
Announcement Date01/24/201401/27/201501/28/2016

© 4-traders.com 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRISTOL-MYERS SQUIBB CO
01/23BRISTOL-MYERS SQUIBB CO : annual earnings release
01/21 BRISTOL MYERS SQUIBB : Opdivo news hits Bristol-Myers
01/20 Procter & Gamble, Skyworks gain; Bristol-Myers Squibb sinks
01/20 BRISTOL MYERS SQUIBB : and Ono Pharmaceutical Company Enter Settlement and Licen..
01/20 European shares ease ahead of Trump inauguration
01/20 Bristol-Myers shares fall on lung cancer timeline setback
01/20 BRISTOL MYERS SQUIBB : Provides Regulatory Update in First-line Lung Cancer
01/19 FINDINGS ON IMMUNOGLOBULINS DETAILED : ...
01/19 BRISTOL MYERS SQUIBB : An Application for the Trademark "ORBRODA" Has Been Filed..
01/19 BRISTOL MYERS SQUIBB : Patent Issued for Alkyl Amide-Substituted Pyrimidine Comp..
More news
Sector news : Pharmaceuticals - NEC
07:24p MORGAN STANLEY : Toronto biotech raises $200 million ahead of ADHD drug decision
01:30pDJJOHNSON & JOHNSON : Revenue Rises But Forecast Disappoints
12:35a U.S. reaches settlement with Endo on pay-for-delay charges
01/20 European shares ease ahead of Trump inauguration
01/20 Bristol-Myers shares fall on lung cancer timeline setback
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01/23 I'm Buying Bristol-Myers Squibb Here At 52-Week Lows
01/23 BIOTECH FORUM DAILY DIGEST : : Opdivo's Setback - Focus Feature On Fibrogen
01/23 Roche Challenges Keytruda's Colorectal Cancer Pole Position
01/23 Bristol Looks To Exploit Opdivo's Liver Cancer Advantage
01/23 Bristol Catches A Break At Last
Advertisement
Financials ($)
Sales 2016 19 314 M
EBIT 2016 5 345 M
Net income 2016 4 665 M
Debt 2016 186 M
Yield 2016 3,13%
P/E ratio 2016 18,17
P/E ratio 2017 17,70
EV / Sales 2016 4,34x
EV / Sales 2017 4,16x
Capitalization 83 561 M
More Financials
Chart BRISTOL-MYERS SQUIBB CO
Duration : Period :
Bristol-Myers Squibb Co Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQU...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 59,6 $
Spread / Average Target 19%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Giovanni Caforio Chief Executive Officer & Director
Lamberto Andreotti Chairman
Charles A. Bancroft Chief Financial Officer & Executive Vice President
Francis M. Cuss Chief Scientific Officer & Executive VP
Paul von Autenried Chief Information Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB C..-14.44%83 561
JOHNSON & JOHNSON-1.13%309 896
ROCHE HOLDING LTD.0.39%200 025
PFIZER INC.-3.14%190 910
NOVARTIS AG-4.32%183 809
MERCK & CO., INC.4.99%170 419
More Results